MA43313A - Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation - Google Patents

Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation

Info

Publication number: MA43313A
Authority: MA; Morocco
Prior art keywords: aza; manufacturing; methods; opioid receptor; receptor modulators
Prior art date: 2015-09-02

Application number

MA043313A

Other languages

English (en)

Other versions

MA43313B1 (fr

Inventor

Kargbo Robert Borbo

Michael John Hawkins

Robert Jason Herr

Guodong Liu

Daubert Tamara Ann Miskowski

Gregory J Pacofsky

Philip Michael Pitis

Donna Romero

Aimee Crombie Speerschneider

Dennis Shinji Yamashita

Catherine C K Yuan

Original Assignee

Trevena Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-02

Filing date

2016-08-30

Publication date

2018-10-03

2016-08-30 Application filed by Trevena Inc filed Critical Trevena Inc

2018-10-03 Publication of MA43313A publication Critical patent/MA43313A/fr

2022-06-30 Publication of MA43313B1 publication Critical patent/MA43313B1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA43313A 2015-09-02 2016-08-30 Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation MA43313B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562213203P	2015-09-02	2015-09-02
PCT/US2016/049526 WO2017040545A1 (fr)	2015-09-02	2016-08-30	Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation

Publications (2)

Publication Number	Publication Date
MA43313A true MA43313A (fr)	2018-10-03
MA43313B1 MA43313B1 (fr)	2022-06-30

Family

ID=58188367

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA43313A MA43313B1 (fr)	2015-09-02	2016-08-30	Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation

Country Status (22)

Country	Link
US (3)	US10246436B2 (fr)
EP (2)	EP4086249A3 (fr)
JP (2)	JP6898310B2 (fr)
KR (1)	KR102787317B1 (fr)
CN (2)	CN114773318A (fr)
AU (2)	AU2016315720B2 (fr)
CA (1)	CA3015702A1 (fr)
CY (1)	CY1125225T1 (fr)
DK (1)	DK3344248T3 (fr)
ES (1)	ES2920130T3 (fr)
HR (1)	HRP20220735T1 (fr)
HU (1)	HUE058819T2 (fr)
IL (1)	IL257503B (fr)
LT (1)	LT3344248T (fr)
MA (1)	MA43313B1 (fr)
MD (1)	MD3344248T2 (fr)
PL (1)	PL3344248T3 (fr)
PT (1)	PT3344248T (fr)
RS (1)	RS63319B1 (fr)
SI (1)	SI3344248T1 (fr)
SM (1)	SMT202200377T1 (fr)
WO (1)	WO2017040545A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102662065B1 (ko) *	2017-02-17	2024-05-07	트레베나, 인코포레이티드.	7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
US11702408B2 (en)	2017-02-17	2023-07-18	Trevena, Inc.	5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN111533682B (zh) *	2020-05-29	2022-03-01	清华大学	帕罗西汀及其类似物的制备方法
CN113880815B (zh) *	2020-07-03	2024-03-29	中国药科大学	一类吲哚衍生物及其制备方法和用途
EP4236939A4 (fr) *	2020-10-27	2024-08-07	Trevena, Inc.	Formes cristallines et amorphes d'un modulateur delta-opioïde
JP2022135015A (ja) *	2021-03-04	2022-09-15	国立大学法人東京工業大学	オピオイド受容体作動剤
WO2023070605A1 (fr) *	2021-10-29	2023-05-04	Trevena, Inc.	Procédés de préparation de composés modulateurs du récepteur delta-opioïde contenant un aza-hétérocycle à 6 chaînons

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE352811B (fr)	1971-06-04	1973-01-15	Pharmacia Ab
US3960150A (en)	1971-09-09	1976-06-01	Alza Corporation	Bioerodible ocular device
US3867519A (en)	1972-04-27	1975-02-18	Alza Corp	Bioerodible drug delivery device
SE375007B (fr)	1972-11-30	1975-04-07	Pharmacia Ab
US3963025A (en)	1974-09-16	1976-06-15	Alza Corporation	Ocular drug delivery device
JPS5825980B2 (ja)	1976-02-12	1983-05-31	ヤマサ醤油株式会社	サイクリックヌクレオチドの定量法
US4186184A (en)	1977-12-27	1980-01-29	Alza Corporation	Selective administration of drug with ocular therapeutic system
US4303637A (en)	1980-04-04	1981-12-01	Alza Corporation	Medication indicated for ocular hypertension
DK231088D0 (da) *	1988-04-28	1988-04-28	Ferrosan As	Piperidinforbindelser, deres fremstilling og anvendelse
US5086063A (en)	1988-03-28	1992-02-04	Du Pont Merck Pharmaceutical Company	4-aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof
US5401629A (en)	1990-08-07	1995-03-28	The Salk Institute Biotechnology/Industrial Associates, Inc.	Assay methods and compositions useful for measuring the transduction of an intracellular signal
US5443505A (en)	1993-11-15	1995-08-22	Oculex Pharmaceuticals, Inc.	Biocompatible ocular implants
US5869079A (en)	1995-06-02	1999-02-09	Oculex Pharmaceuticals, Inc.	Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6462048B2 (en) *	1996-03-29	2002-10-08	Pfizer Inc.	Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors
WO1998000401A1 (fr)	1996-06-28	1998-01-08	Merck & Co., Inc.	Promedicaments antagonistes de recepteurs de fibrinogenes
JP4498602B2 (ja) *	1998-03-10	2010-07-07	リサーチ・トライアングル・インスティチュート	新規なオピエート化合物、その調製法及び使用法
WO2001032178A1 (fr)	1999-10-29	2001-05-10	Novo Nordisk A/S	Utilisation de piperidines 3,4-substituees
AU2001273040A1 (en)	2000-06-27	2002-01-08	Du Pont Pharmaceuticals Company	Factor xa inhibitors
US6995144B2 (en)	2002-03-14	2006-02-07	Eisai Co., Ltd.	Nitrogen containing heterocyclic compounds and medicines containing the same
CN100372850C (zh) *	2003-02-12	2008-03-05	神经研究公司	新的8-氮杂-双环[3.2.1]辛烷衍生物和它们作为单胺神经递质再摄取抑制剂的用途
SE0301445D0 (sv) *	2003-05-16	2003-05-16	Astrazeneca Ab	Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
CA2540061A1 (fr)	2003-09-30	2005-04-14	Merck & Co., Inc.	Antagonistes du recepteur de la tachykinine a base de phenyle pyrrolidine ether
US7488745B2 (en)	2004-07-16	2009-02-10	Schering Corporation	Compounds for the treatment of inflammatory disorders
US7504424B2 (en)	2004-07-16	2009-03-17	Schering Corporation	Compounds for the treatment of inflammatory disorders
DE602005023172D1 (de)	2004-07-16	2010-10-07	Schering Corp	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
US7098203B2 (en)	2004-07-20	2006-08-29	Bristol-Myers Squibb Company	Homopiperidine derivatives as NK-1 antagonists
US7872023B2 (en)	2005-02-17	2011-01-18	Research Triangle Institute	Kappa opioid receptor ligands
TW200804307A (en)	2005-10-27	2008-01-16	Synta Pharmaceuticals Corp	Process for preparing mesylate salts of IL-12 inhibitory compounds
KR101091376B1 (ko)	2005-12-01	2011-12-07	에프. 호프만-라 로슈 아게	세로토닌 수송체(ｓｅｒｔ) 억제제
US20070142389A1 (en)	2005-12-20	2007-06-21	Pfizer Inc.	Piperidine derivatives
MX2008011615A (es)	2006-03-14	2008-09-22	Amgen Inc	Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos.
ES2439581T3 (es)	2006-12-04	2014-01-23	Orexo Ab	Nueva composición farmacéutica no susceptible de abuso que comprende opioides
WO2008145616A1 (fr) *	2007-05-25	2008-12-04	Abbott Gmbh & Co. Kg	Composés hétérocycliques comme modulateurs positifs du récepteur métabotropique du glutamate 2 (récepteur mglu2)
BRPI0815658A2 (pt)	2007-08-07	2015-02-18	Hoffmann La Roche	Aril-éter pirrolidina como antagonistas do receptor nk3
CA2705835A1 (fr)	2007-11-16	2009-05-22	Neuraxon, Inc.	Composes d'indole et procedes de traitement de la douleur viscerale
US8664214B2 (en)	2010-03-30	2014-03-04	AbbVie Deutschland GmbH & Co. KG	Small molecule potentiators of metabotropic glutamate receptors I
US8507535B2 (en)	2010-07-07	2013-08-13	Hoffmann-La Roche Inc.	Methyl-pyrrolidine ether derivatives
DK2675893T3 (en) *	2011-02-18	2019-04-15	Scripps Research Inst	Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
WO2012129562A2 (fr)	2011-03-24	2012-09-27	The Scripps Research Institute	Composés et procédés pour l'induction de la chondrogenèse
BR112014010271A2 (pt)	2011-10-31	2017-04-18	Xenon Pharmaceuticals Inc	compostos de benzenossulfonamida e seu uso como agentes terapêuticos
CN104039777B (zh)	2012-01-31	2016-03-02	卫材R&D管理有限公司	帕罗西汀衍生物
WO2013182612A1 (fr)	2012-06-07	2013-12-12	Bayer Pharma Aktiengesellschaft	Inhibiteurs de transport du glucose
ES2653265T3 (es) *	2012-12-28	2018-02-06	Purdue Pharma Lp	Morfinanos sustituidos y el uso de éstos
EP3183232B1 (fr)	2014-08-22	2023-05-03	The Arizona Board of Regents on behalf of The University of Arizona	Dérivés de 1-aryléthyl-4-acylaminopipéridine substitués à titre de modulateurs des récepteurs d'opioïdes/adrénorécepteurs alpha et leur procédé de préparation
ES2913117T3 (es) *	2015-06-26	2022-05-31	Univ Michigan Regents	Inhibidores de quinasa receptora acoplada a proteína G y métodos para el uso de los mismos

2016
- 2016-08-30 RS RS20220588A patent/RS63319B1/sr unknown
- 2016-08-30 HR HRP20220735TT patent/HRP20220735T1/hr unknown
- 2016-08-30 EP EP22161847.3A patent/EP4086249A3/fr not_active Withdrawn
- 2016-08-30 WO PCT/US2016/049526 patent/WO2017040545A1/fr not_active Ceased
- 2016-08-30 US US15/252,112 patent/US10246436B2/en active Active
- 2016-08-30 CN CN202210425041.XA patent/CN114773318A/zh active Pending
- 2016-08-30 SI SI201631546T patent/SI3344248T1/sl unknown
- 2016-08-30 MA MA43313A patent/MA43313B1/fr unknown
- 2016-08-30 MD MDE20180679T patent/MD3344248T2/ro unknown
- 2016-08-30 CN CN201680055385.9A patent/CN108025002B/zh active Active
- 2016-08-30 ES ES16842832T patent/ES2920130T3/es active Active
- 2016-08-30 PL PL16842832.4T patent/PL3344248T3/pl unknown
- 2016-08-30 KR KR1020187008816A patent/KR102787317B1/ko active Active
- 2016-08-30 AU AU2016315720A patent/AU2016315720B2/en not_active Ceased
- 2016-08-30 CA CA3015702A patent/CA3015702A1/fr active Pending
- 2016-08-30 PT PT168428324T patent/PT3344248T/pt unknown
- 2016-08-30 LT LTEPPCT/US2016/049526T patent/LT3344248T/lt unknown
- 2016-08-30 HU HUE16842832A patent/HUE058819T2/hu unknown
- 2016-08-30 JP JP2018511436A patent/JP6898310B2/ja active Active
- 2016-08-30 SM SM20220377T patent/SMT202200377T1/it unknown
- 2016-08-30 DK DK16842832.4T patent/DK3344248T3/da active
- 2016-08-30 EP EP16842832.4A patent/EP3344248B1/fr active Active
2018
- 2018-02-13 IL IL257503A patent/IL257503B/en unknown
2019
- 2019-02-27 US US16/286,700 patent/US11465980B2/en active Active
2021
- 2021-05-24 AU AU2021203337A patent/AU2021203337A1/en not_active Abandoned
- 2021-06-09 JP JP2021096263A patent/JP7463318B2/ja active Active
2022
- 2022-06-22 CY CY20221100431T patent/CY1125225T1/el unknown
- 2022-08-03 US US17/879,923 patent/US20230203002A1/en active Pending

Also Published As

Publication number	Publication date
ES2920130T3 (es)	2022-08-01
KR102787317B1 (ko)	2025-03-26
MA43313B1 (fr)	2022-06-30
EP3344248A1 (fr)	2018-07-11
IL257503A (en)	2018-04-30
US11465980B2 (en)	2022-10-11
WO2017040545A1 (fr)	2017-03-09
IL257503B (en)	2021-10-31
JP2021138744A (ja)	2021-09-16
CN114773318A (zh)	2022-07-22
JP2018527354A (ja)	2018-09-20
NZ739934A (en)	2024-07-05
SI3344248T1 (sl)	2022-07-29
EP4086249A3 (fr)	2023-02-15
EP3344248B1 (fr)	2022-03-23
DK3344248T3 (da)	2022-06-20
JP7463318B2 (ja)	2024-04-08
AU2016315720A1 (en)	2018-03-15
HRP20220735T1 (hr)	2022-09-02
HK1257927A1 (en)	2019-11-01
US10246436B2 (en)	2019-04-02
HK1254498A1 (zh)	2019-07-19
SMT202200377T1 (it)	2022-11-18
PT3344248T (pt)	2022-06-29
MD3344248T2 (ro)	2022-10-31
US20230203002A1 (en)	2023-06-29
CA3015702A1 (fr)	2017-03-09
HUE058819T2 (hu)	2022-09-28
EP4086249A2 (fr)	2022-11-09
AU2016315720B2 (en)	2021-02-25
US20190202803A1 (en)	2019-07-04
CY1125225T1 (el)	2025-03-28
KR20180041751A (ko)	2018-04-24
AU2021203337A1 (en)	2021-06-24
RS63319B1 (sr)	2022-07-29
PL3344248T3 (pl)	2022-07-18
LT3344248T (lt)	2022-06-27
JP6898310B2 (ja)	2021-07-07
CN108025002B (zh)	2022-05-13
US20170210725A1 (en)	2017-07-27
EP3344248A4 (fr)	2019-07-10
CN108025002A (zh)	2018-05-11
US20200231564A9 (en)	2020-07-23

Publication	Publication Date	Title
MA43313A (fr)	2018-10-03	Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
MA43827A (fr)	2018-11-28	Composés di-nucléotides cycliques et leurs procédés d'utilisation
EP3504213A4 (fr)	2020-01-15	Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr)	2019-11-27	Composés anti-crispr et leurs procédés d'utilisation
MA49858A (fr)	2021-04-28	Composés, compositions et procédés
MA54252A (fr)	2022-04-27	Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
EP3676297A4 (fr)	2021-04-28	Composés, compositions et procédés
EP3335034A4 (fr)	2019-04-10	Électrodes à l'état solide, procédés de fabrication et méthodes d'utilisation en détection
MA42055A (fr)	2018-03-14	Composés antimicrobiens et procédés de fabrication et d'utilisation de ceux-ci
EP3298168A4 (fr)	2019-02-20	Agents réducteurs stabilisés et leurs procédés d'utilisation
EP3380101A4 (fr)	2019-05-22	Composés inhibiteurs d'eif4-a et procédés associés
MA46427A (fr)	2018-08-15	Compositions d'oligonucléotides et procédés associés
MA49560A (fr)	2020-05-20	Composés cétoniques bicycliques et leurs procédés d'utilisation
EP3316894A4 (fr)	2019-06-19	Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
EP3322666A4 (fr)	2019-03-20	Dispositifs à réactance accordable et leurs procédés de fabrication et d'utilisation
MA39915A (fr)	2017-03-22	Composés de pladiénolide pyridine et leurs procédés d'utilisation
EP3377060A4 (fr)	2019-04-24	Composés de pyrazole, procédés de production et utilisation
MA42612A (fr)	2018-06-20	Composés hétérocycliques fumagillol, et procédés correspondants de fabrication et d'utilisation
EP3459323A4 (fr)	2020-01-01	Chambres de pulvérisation et leurs procédés d'utilisation
EP3349851A4 (fr)	2019-04-24	Polypeptides photosensibles et leurs procédés d'utilisation
EP3380215A4 (fr)	2019-05-08	Compositions pour systèmes d'adsorption de nox passive (pna) et leurs procédés de fabrication et d'utilisation
EP3364986A4 (fr)	2019-11-27	Compositions de plasma et leurs procédés d'utilisation
EP3303436A4 (fr)	2019-02-20	Hydrofluorooléfines et leurs procédés d'utilisation
EP3364984A4 (fr)	2019-09-25	Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
EP3526205A4 (fr)	2020-05-27	Composés thérapeutiques et leurs procédés d'utilisation